NCT04038970View on ClinicalTrials.gov

Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate

PHASE2CompletedINTERVENTIONAL
Enrollment

145

Participants

Timeline

Start Date

November 8, 2019

Primary Completion Date

July 28, 2022

Study Completion Date

July 28, 2022

Conditions
Rheumatoid Arthritis
Interventions
BIOLOGICAL

KN019, 5mg/kg

Solution, intravenous, 5 mg/kg

BIOLOGICAL

KN019, 10 mg/kg

Solution, intravenous, 10 mg/kg

BIOLOGICAL

Placebo

Solution, intravenous, Placebo

COMBINATION_PRODUCT

Methotrexate

Tablets, oral, 7.5-25 mg weekly to be adjusted according to patient condition

Trial Locations (1)

337055

Pingxiang people's hospital, Pingxiang

All Listed Sponsors
lead

Jiangsu Alphamab Biopharmaceuticals Co., Ltd

INDUSTRY

NCT04038970 - Efficacy and Safety Study of KN019 in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate | Biotech Hunter | Biotech Hunter